Merck & Co., Inc. $MRK Shares Sold by ABN AMRO Bank N.V.

Key Points

• ABN AMRO Bank slashed its Merck stake by 90% in the fourth quarter, selling 1.73 million shares and ending with 191,811 shares valued at about $20.2 million.
• Merck reported better-than-expected first-quarter results, with EPS of ($1.28) versus estimates of ($1.47) and revenue of $16.29 billion, up 4.9% year over year.
• Investor sentiment remains mixed: analysts currently rate the stock a Moderate Buy on average, while recent news highlights both pipeline progress and a potential risk from the upcoming Gardasil trial.

ABN AMRO Bank N.V. cut its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 90.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 191,811 shares of the company's stock after selling 1,727,191 shares during the period. ABN AMRO Bank N.V.'s holdings in Merck & Co., Inc. were worth $20,173,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in MRK. Pure Financial Advisors LLC lifted its position in shares of Merck & Co., Inc. by 5.2% in the 4th quarter. Pure Financial Advisors LLC now owns 57,136 shares of the company's stock valued at $6,014,000 after acquiring an additional 2,840 shares in the last quarter. Osprey Private Wealth LLC lifted its position in shares of Merck & Co., Inc. by 92.1% in the 4th quarter. Osprey Private Wealth LLC now owns 29,240 shares of the company's stock valued at $3,078,000 after acquiring an additional 14,015 shares in the last quarter. Dynamic Wealth Strategies LLC lifted its position in shares of Merck & Co., Inc. by 49.6% in the 4th quarter. Dynamic Wealth Strategies LLC now owns 1,343 shares of the company's stock valued at $141,000 after acquiring an additional 445 shares in the last quarter. Income Insurance Ltd purchased a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at approximately $793,000. Finally, D Orazio & Associates Inc. lifted its position in Merck & Co., Inc. by 50.7% in the 4th quarter. D Orazio & Associates Inc. now owns 3,743 shares of the company's stock worth $394,000 after buying an additional 1,260 shares in the last quarter. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Price Performance

Shares of Merck & Co., Inc. stock opened at $111.26 on Monday. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $125.14. The firm has a fifty day moving average price of $117.07 and a two-hundred day moving average price of $108.31. The company has a market cap of $274.78 billion, a PE ratio of 31.34, a price-to-earnings-growth ratio of 2.51 and a beta of 0.18.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating analysts' consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The firm had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. During the same period in the prior year, the firm earned $2.22 EPS. The business's revenue was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Analysts expect that Merck & Co., Inc. will post 5.16 EPS for the current year.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck published a landmark Science paper on a new large-scale biocatalytic synthesis method for its investigational oral PCSK9 inhibitor, enlicitide decanoate. The work supports manufacturing scalability for a potential future cardiovascular drug and underscores progress in Merck’s pipeline. Article Title
• Positive Sentiment: Merck also became the sole testing provider for Genetix Biotherapeutics’ FDA-approved gene therapies under a five-year agreement, strengthening its BioReliance services business and adding a recurring commercialization-related revenue stream. Article Title
• Neutral Sentiment: Analyst commentary highlighted Merck as a well-prepared dividend stock despite its upcoming patent cliff, suggesting the market is still weighing long-term earnings durability rather than reacting to a single catalyst. Article Title
• Negative Sentiment: Merck is heading toward a July 27 trial over Gardasil safety claims after the vaccine reached an $8.9 billion sales peak. The litigation risk could weigh on sentiment around one of Merck’s key growth franchises, even though the company continues to defend the product’s safety record. Article Title

Wall Street Analysts Forecast Growth

MRK has been the subject of a number of research analyst reports. Citigroup initiated coverage on shares of Merck & Co., Inc. in a research report on Wednesday, May 6th. They issued a "neutral" rating and a $125.00 target price for the company. Guggenheim increased their target price on shares of Merck & Co., Inc. from $122.00 to $140.00 and gave the stock a "buy" rating in a research report on Friday, February 6th. Zacks Research upgraded shares of Merck & Co., Inc. from a "strong sell" rating to a "hold" rating in a research report on Tuesday, March 17th. UBS Group increased their target price on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a "buy" rating in a research report on Monday, April 13th. Finally, Barclays initiated coverage on shares of Merck & Co., Inc. in a research report on Friday, February 20th. They issued an "overweight" rating and a $140.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $128.18.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.